Non-Compliant Balloons Improve Bifurcation Outcomes

Courtesy of Dr. Carlos Fava.

non compliant balloonsThe provisional approach is the standard strategy to treat bifurcations, but it might cause dissection of the ostium, a serious complication of the side branch. The use of non-compliant balloons (NCB) ensures uniform, constant, and controlled expansion along balloon length, reducing the risk of dissection.

The COBIS II registry enrolled 2,897 patients with bifurcation lesions (≥2.5 mm main vessel and ≥2.3 mm side branch diameters).

26% (752 patients) were treated with NCB. After propensity score matching, there were 710 patients in each group.

Procedural success was higher in patients receiving NCB:

 

With NCB: 79%

Without NCB: 73.9%

[p=0.01]

 

Angiographic success of side branch was:

 

With NCB: 79.7 %

Without NCB: 75.4%

[p=0.03].

 

The use of NCB positively correlated with lower SB dissection (0.1% vs. 1.1%; p=0.04)

Follow up was at 36 months in 96.3% of the population. Combined events rate resulted lower in the NCB group (HR 0.64, CI 95% 0.46-0.91; p=0.01), same as cardiac death (HR 0.14, CI 95% 0.03-0. 64; p=0.01) and stent thrombosis (probable, definite and possible) and there was a tendency towards a lower target vessel revascularization rate.

 

Conclusion

The use of non-compliant balloons was associated to a lower rate of events after PCI at long term in patients with bifurcation lesions in coronary arteries.

 

Editorial Comment

Bifurcations are gaining in complexity, as more experienced operators and new stents advance over more challenging lesions.

The new advancement in balloons to improve stent implantation and the new suggested techniques such as proximal optimization (POT) will ensure better results in more and more complex lesions.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

 

Original Title: Impact of non-compliant balloons on long-term clinical outcomes in coronary bifurcation lesion: results from the COBIS (COronary BIfurcation Stent) II registry

Reference: Taek Kyu Park, et al. EuroIntervention2016;12:456-464

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...